BIO Asia–Taiwan

Conference Highlights 🤝 Regional Collaboration Forum 🤝 For the very first time, the Taiwan BIO collaborated with the Taiwan External Trade Development Council (TAITRA) to co-host the Regional Collaboration Forum, which Australia, Japan, Belgium, Thailand, India, and Malaysia also each host their own country-specific forum with a total of 40 companies participating to explore cross nation collaboration opportunities. During the Plenary Session, representatives from each country shared insights on their respective industries. Helen Dai, Trade and Investment Commissioner, Australia Trade and Investment Commission (Austrade), highlighted Australia's strengths in clinical trials, including the government's efficient approval process and favorable policies for talent and immigration, making Australia a top destination for clinical trials. Els Verhulst, Science & Technology Counselor, FLANDERS INVESTMENT & TRADE, Embassy of Belgium in Tokyo, Japan, noted that Belgium is a major powerhouse in life sciences and pharmaceuticals, with the highest per capita investment in medical R&D in Europe, making it one of the world's top three "Medicine Valleys." Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association (JBA), stated that Japan has globally leading capabilities in biotech and biopharmaceutical research. In recent years, Japan's biotech industry has placed a strong emphasis on innovation, especially in areas such as bio-pharmaceuticals, regenerative medicine, and gene editing. From Thailand, Nares Damrongchai, Co-Founder, Accel Group Co., Ltd. and former Director of the National TCELS Program, shared insights on the development of life sciences and diagnostic testing in Thailand, along with the nation's experience in international cooperation through the Asia-Pacific Economic Cooperation (APEC). Murali Panchapagesa Muthuswamy, former chairman of the Indian Biotech Industry Association, proposed collaborations between Taiwan's R&D and India's manufacturing capabilities, encouraging the use of India's production capacities for pharmaceuticals and vaccines. Representatives from all participating countries expressed a strong desire for increased cooperation in regulatory review across Asia, which would help biotech and pharmaceutical companies unlock international market opportunities. This collaboration aims to expand the scope of each country's biotech industry, fostering win-win and even multi-win situations, injecting new vitality into industry development and creating new opportunities across borders. Full Photo Albums: Plenary Session: https://lnkd.in/gUy_2mRh Belgium Session: https://lnkd.in/gxr3MU_S Japan Session: https://lnkd.in/gjECKmyC Thailand Session: https://lnkd.in/gep5Cgey India Session: https://lnkd.in/g4S5j4ys Malaysia Session: https://lnkd.in/gX56yzGi

Conference Highlights 🔥 Investment Summit🔥 This year's new track - Investment Summit - through venture capitals' selections, invited a total of 48 domestic and international outstanding biotech companies to present, including new drug development, digital therapeutics, AI applications in clinical trials, drug development, and imaging, reflecting venture capitalists' optimism about their future potential. The involvement of international venture capital firms has also seen a significant rise. Over 50 international investment institutions attended the event. Notable foreign participants included Flagship Pioneering and Illumina Ventures, UK-based Syncona, Prime Ventures, Vivo Capital, Israel's largest pharma venture fund aMoon, Pegasus Tech Ventures, Japan's DCI Partners, Axil Capital Partners, and more. 👉 Full Photo Album: https://lnkd.in/g2bSHTfx The speakers included: ✨Jorge Cortell, Senior Advisor Health & Life Sciences, Harvard University Innovation Laboratories ✨Jenny Yang, Head of External Innovation Asia Pacific, Novo Nordisk A/S ✨Jo Shen, Ph.D., Venture Partner, Vivo Capital ✨Alice Chen, PhD, Executive VP, Accelerator Life Science Partner ✨Gaurav Aggarwal, MD, Managing Partner, Vivo Capital ✨Gur Roshwalb, MD/PhD, Partner, aMoon Fund ✨John Tsai, MD, Executive Partner, Syncona ✨Yenchen Huang, VP, Diamond Biofund ✨Stephanie Marrus, Managing Director, Entrepreneurship, University of California San Francisco The pitching companies in MedTech & Digital Health were: 🎯aetherAI 雲象科技 🎯AIxMed, Inc. 🎯ANEUVO 🎯APrevent Biotech GmbH 🎯BioAro Inc. 🎯Bonraybio Corporation 🎯Brain Navi Biotechnology Co., Ltd. 🎯FaceHeart 🎯Flat Medical, Inc. 🎯Genialis 🎯HCmed Innovations Co., Ltd. 🎯JelloX Biotech Inc. 🎯oxipit The pitching companies in Therapeutics & Pharmaceuticals were: ⭐AcadeMab Biomedical ⭐ACCELERATED BIOSCIENCES CORP. ⭐Acepodia ⭐AiViva Biopharma, Inc. ⭐Elixiron Immunotherapeutics ⭐Allgenesis Biotherapeutics Inc. ⭐AmMax Bio., Inc. ⭐安宏生醫 ⭐AnnJi Pharmaceutical Co., Ltd. ⭐AP Biosciences ⭐Apexcella Biomedical ⭐Apeximmune Therapeutics ⭐Cellusion Inc. ⭐Cyto-Facto Inc. ⭐DotBio ⭐GEXVal ⭐HanchorBio Inc. 漢康生技股份有限公司 ⭐Help Therapeutics ⭐Immunwork ⭐LBL Biotech ⭐順天醫藥生技股份有限公司 ⭐浩鼎生技股份有限公司 ⭐Ochre Bio ⭐Onward Therapeutics ⭐REGiMMUNE ⭐Rock BioMedical ⭐TFBS Bioscience, Inc. ⭐TMS ⭐TriArm Therapeutics ⭐TWi Biotechnology 安成生物科技股份有限公司 ⭐United Immunity, Co., Ltd. ⭐Xgene Pharmaceutical ⭐XWPharma

Conference Highlights Session 13 – Shaping the Future of Digital Health Held over lunch, Session 13 opened with talks by Chien-Cheng Tai, Senior Technical Specialist, Department of Industrial Technology, Ministry of Economic Affairs; and Eric Y. Chuang, Director of the Biomedical Technology and Device Research Laboratories (BDL), ITRI. Nipun Jain, Director of AstraZeneca's Innovation and Partnerships, International Region, introduced the establishment of AstraZeneca's A.Catalyst Network, which is dedicated to promoting innovative therapies in Asia, East Asia, Africa, and Latin America. Tony Lee, Head of Sales, Google Cloud Taiwan, discussed various applications of Google AI in the healthcare field. In the subsequent discussion, moderated by Chuang, the two speakers, along with Jing-Wei Lee, Superintendent, National Cheng Kung University Hospital; Kai-Cheng Hsu, Chief Medical Officer, Biomedical Big Data & Artificial Intelligence Technology, BDL, ITRI; and Peter Kurz, Chief Strategy Officer, QIC, explored strategies for promoting precision medicine through policies and public-private partnerships. #StayTunedForMorePhotosAndHighlights #BIOAsiaTaiwan2024

Conference Highlights Session 12– Advances in Genetics and Precision Medicine in Human Diseases Precision medicine is a discipline that continues to evolve. In this session we'll examine the latest advancements and applications in this field from a distinguished panel of experts within both precision medicine and precision health domains. We'll discover how genomic profiling and personalized treatment strategies are revolutionizing breast cancer care, making a real difference to patient outcomes. Additionally, we'll highlight breakthroughs in precision respiratory medicine, such as individualized plans for asthma and chronic obstructive pulmonary disease (COPD), leveraging genetic and biomarker data. Attendees will gain insights into the latest research, clinical practices, and future directions in precision medicine and in the wider-scoped field of precision health. Please join us to learn how precision medicine is transforming healthcare by providing more personalized and effective treatments. Chaired by Kang-Yuan Lee, Vice President of Taipei Medical University. Toyomasa Katagiri, Director of Japan's National Institutes of Biomedical Innovation, Health and Nutrition (#NIBIOHN 国立研究開発法人 医薬基盤・健康・栄養研究所), shared his team's development of a new mechanism for breast cancer therapy. John Jiang, Senior Director of Medical & Scientific Affairs at Illumina, discussed the application of genomic analysis in personalized cancer therapy. Kazuhiro Ito, Professor at 英國倫敦帝國學院, shared developments in precision respiratory medicine. The post-discussion was chaired by Teh-Ying Chou, Vice Superintendent, Research and Development, Taipei Medical University Hospital. Sungmei Hsiung, Partner at DDT Attorneys-at-Law, specifically reminded technology developers to use patent tools to protect their research. #StayTunedForMorePhotosAndHighlights #BIOAsiaTaiwan2024

Conference Highlights Session 11 – AI for Pharma Session 11, focused on the application of AI in the pharmaceutical field. Hosted by Ching-Yung lin, founder of Graphen Drugnomics, representatives from a number of domestic and international companies that either use AI to develop drugs, or provide AI services, shared their experiences. Tom Diethe, Head of 英國阿斯利康's Centre for Artificial Intelligence, out of Cambridge, UK, shared how AZ uses AI tools to aid drug development. Martin Akerman, Co-Founder and CTO of the American AI drug discovery company Envisagenics, introduced their technology that uses AI to identify RNA splicing errors in tumor cells to develop innovative therapeutic targets. Thomas Evangelidis, Founder and CEO of AI|ffinity, discussed how his company uses protein NMR (nuclear magnetic resonance) data combined with AI for its drug discovery process. Shu-Chen Chen, Chief Scientific Officer of 安宏生醫, shared how AnHorn integrates AI into the drug design and discovery process to accelerate the development of innovative protein degradation drugs. NaHyun Kim, Solution Sales Specialist at Medidata Solutions, explained how Medidata's AI division applies AI and machine learning (AI/ML) technologies in clinical trials. During the post-session discussion, Ching-Yung Lin mentioned that while AI has become extremely popular in the past five years, there is still much anticipation about whether AI will truly transform the pharmaceutical industry over the coming 20-30 years. #StayTunedForMorePhotosAndHighlights #BIOAsiaTaiwan2024

📢 Event Sharing Two Weeks Left to Apply for Startup Spotlight at BIO-Europe 2024! Sponsored by #Bayer this year, on Tuesday, 5 November 2024 from 15:00 - 17:00 they will be holding the Startup Spotlight Pitch Competition during #BIOEurope. The #StartupSpotlightPitchCompetition is a platform for startups to get in front of potential investors and pharma partners, plus for those partners to have access to a curated pool of innovative companies.   If you are interested in presenting and fit the criteria, please fill out the application and they will be in touch: https://lnkd.in/gQdxjJsc     Applications for pitching can be submitted for consideration by startup companies who meet the following criteria:   👉 Company created in the past three years, or innovation incubated within a company for a maximum of three years 👉 Developing new therapeutic solutions, technology and digital platforms 👉 Aggregate funding of €10 million or less 👉 Company with less than 20 employees   More information about the Startup Spotlight here: https://lnkd.in/gf7zueFY

Conference Highlights Session 10 – Translational Medicine, A Journey from Novelty to Commercial Success This session explores the dynamic field of translational medicine, highlighting its journey from innovative research to commercial triumph. Delve into the critical elements and processes that bridge the gap between laboratory discoveries and marketable therapies. Case studies of recent breakthroughs will illustrate how novel scientific insights are transformed into commercially viable treatments, addressing unmet medical needs. Topics will include strategic partnerships, regulatory pathways, scalable manufacturing practices that ensure clinical efficacy and safety, and an examination of successful funding mechanisms. Attendees will gain valuable knowledge around navigating the complexities of translational medicine, and will learn how to effectively translate cutting-edge research into life-changing therapies, driving innovation and improving patient outcomes. Session 10 began with Jingrong Jean Cui, President and CEO of BlossomHill Therapeutics, Inc., to discuss three oncology drugs she led in development— #crizotinib, #lorlatinib, and #repotrectinib —that were approved by the US FDA, detailing her approach from drug design to commercialization. Boyu Zhong, President and Chief Scientist of Tyligand Bioscience, shared the company's process of developing the oral highly-selective c-Met inhibitor Bozitinib from experimental research to clinical trials. He stated that the drug not only shows that c-Met is a promising cancer treatment target but also demonstrates in translational medical research that it can be used to treat non-small cell lung cancer (#NSCLC) and glioblastoma multiforme (#GBM). David Chang, CEO of Taiwan Bio-Pharmaceutical Manufacturing Corp. (#TBMC), detailed the CMC-related difficulties that new drugs might encounter when transitioning from the preclinical stage. Under the moderation of Hsing-Pang Hsieh, Distinguished Research Fellow and Director of the Institute of Biotechnology and Pharmaceutical Research at the National Health Research Institutes, the three speakers also engaged in a comprehensive panel discussion on patent applications for translational drugs, clinical trials, and practical experiences in GMP manufacturing. #StayTunedForMorePhotosAndHighlights #BIOAsiaTaiwan2024

Conference Highlights Session 8 – Strategic Insights into CMC Program Design: Pioneering Biologics Development Excellence For the luncheon Session 8, entitled "Strategic Insights into CMC Program Design: Pioneering Biologics Development Excellence", four biologics manufacturing experts were invited to share their insights on Chemistry, Manufacturing, and Controls (#CMC). Friedmund Bachman, Vice President of OncoOne Research & Development, Austria, outlined the numerous details to consider in CMC process development during biologics R&D. Hsing-Mao Chu, CEO of TE Meds, discussed how his company develops complex next-generation antibody-drug conjugates (#ADCs) through innovative multi-arm linker and proprietary drug bundle technologies. GeneQuantum Healthcare (Suzhou) Co., Ltd Chief Scientist Paul Song shared the development story of his company's ADC technology and the manufacturing advantages brought by its unique antibody drug conjugation technology. Taron Solutions Limited CEO Alan Chang shared global trends and observations in drug CMC design, pointing out that failed drugs are often due to design issues. Therefore, the earlier problems in drug development are identified and resolved, the higher the success rate of the drugs. #StayTunedForMorePhotosAndHighlights #BIOAsiaTaiwan2024

Conference Highlights Session 7 - Taiwan BIO Awards-Successful Stories In Session 7, entitled "Taiwan BIO Awards – Successful Stories", the successful companies from this year's Taiwan BIO Awards were invited to give short presentations on their winning development strategies, technological highlights, and latest innovations. These 19 companies included: Lotus Pharmaceutical, PharmaEssentia, Bonraybio, Pharmosa Biopharm, TSH Biopharm, Steminent Biotherapeutics, Onyx Healthcare, BenQ Dialysis, Acepodia Biotechnologies, ImmunAdd, Sunhawk Vision Biotech, Elixiron Immunotherapeutics, BioGend Therapeutics, Braxx Biotech, Protect Biotech, Formosa Pharmaceuticals, TaiGen Biotechnology, HippoScreen Neurotech, and Syngen Biotech. #StayTunedForMorePhotosAndHighlights #BIOAsiaTaiwan2024

Conference Highlights Session 6 - mRNA and New Therapeutic Modalities New Post-Pandemic Treatment Prospects: mRNA Therapy and Gene Therapy Usher in the Era of Personalized Medicine Session 6, entitled "mRNA and New Therapeutic Modalities", focused on the wide-reaching mRNA technology that that came to prominence during the COVID-19 pandemic. The first speaker was Yusuke Nakamura, President of the National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) in Japan, who shared insights on mRNA cancer vaccines designed to target tumor neoantigens for each patient, aiming to overcome the challenges of immunotherapy. John Tsai, former Head of Global Drug Development and Chief Medical Officer at Novartis, currently a Partner at Syncona, discussed the regulatory challenges faced by popular gene therapies and the future development trends in this field. Eric Huang, Partner at Delos Capital and former General Manager and Chief Scientist of Moderna Genomics, shared insights on mRNA as cancer vaccines, nucleic acid drugs, and the latest global advancements in gene editing therapies. Kevin Chan, Director of Commercial Strategy and Business Development at Kudo Biotechnology, analyzed the practical challenges of mRNA products in process development, quality management, and transportation from a Contract Development and Manufacturing Organization (CDMO) perspective. #StayTunedForMorePhotosAndHighlights #BIOAsiaTaiwan2024